INmune Bio Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
INmune Bio, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue & Gross Profit
Revenue0.010.160.370.180.010.00
Cost of Revenue0.000.000.000.000.000.00
Gross Profit0.010.160.370.180.010.00
Operating Expenses
Research & Development33.1720.2717.0720.545.923.28
Selling, General & Administrative9.489.629.268.796.326.02
Operating Expenses42.6529.9026.3329.3312.247.76
Operating Income-42.64-29.74-25.95-29.15-12.23-7.76
Other Income/Expense
Interest Income0.700.000.000.000.000.00
Interest Expense-0.79-2.28-2.010.000.000.00
Other Income/Expense0.642.01-1.35-1.190.03-0.08
Income
Income Before Tax-42.08-30.01-27.30-30.34-12.10-7.68
Income Tax Expense0.00-6.30-5.73-6.38-2.540.16
Net Income-42.08-30.01-27.30-30.34-12.10-7.68
Net Income - Continuous Operations-42.08-30.01-27.30-30.340.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.00
EBITDA-42.64-29.74-25.95-29.15-12.23-7.68
EBIT-42.64-29.74-25.95-29.15-12.23-7.68
Depreciation & Amortization0.550.000.000.000.000.00
Earnings Per Share
Basic EPS-2.00-2.00-2.00-2.00-1.00-
Diluted EPS-2.00-2.00-2.00-2.00-1.00-1.00
Basic Shares Outstanding19.9417.9817.9316.1311.9910.27
Diluted Shares Outstanding19.9417.9817.9316.1311.9910.27